S.Biomedics Co., Ltd. (KOSDAQ:304360)
27,650
+1,050 (3.95%)
At close: Apr 9, 2026
S.Biomedics Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 6,085 | 4,484 | 1,410 | 4,066 | 6,131 |
Short-Term Investments | 931.4 | 7,746 | 8,175 | 2,346 | 6,750 |
Trading Asset Securities | 7,645 | 11,720 | 1,073 | 1,007 | - |
Cash & Short-Term Investments | 14,661 | 23,950 | 10,658 | 7,419 | 12,881 |
Cash Growth | -38.78% | 124.71% | 43.66% | -42.41% | 3.48% |
Accounts Receivable | 1,610 | 1,753 | 1,922 | 1,246 | 388.8 |
Other Receivables | 104.48 | 206.19 | 198.83 | 204.02 | 67.26 |
Receivables | 1,804 | 2,050 | 2,211 | 1,540 | 456.07 |
Inventory | 1,901 | 2,325 | 2,369 | 1,570 | 763.73 |
Prepaid Expenses | 591 | 404.79 | 336.37 | 426 | 174.46 |
Other Current Assets | 873.29 | 542.39 | 126.94 | 245.98 | 66.43 |
Total Current Assets | 19,831 | 29,272 | 15,700 | 11,201 | 14,342 |
Property, Plant & Equipment | 19,004 | 4,475 | 4,962 | 2,765 | 3,051 |
Long-Term Investments | 1,000 | 500 | 1,533 | 1,000 | 0.06 |
Other Intangible Assets | 327.32 | 407.86 | 118.78 | 153.76 | 25.44 |
Long-Term Deferred Tax Assets | 452.81 | 436.96 | 358.55 | 412.76 | - |
Other Long-Term Assets | 603.5 | 9,509 | 9,275 | 8,825 | 377.05 |
Total Assets | 41,219 | 44,601 | 31,947 | 24,358 | 17,796 |
Accounts Payable | 376.97 | 186.75 | 479.48 | 416.17 | 36.31 |
Accrued Expenses | 255.26 | 266.11 | 294.48 | 253.98 | 182.96 |
Short-Term Debt | 4,294 | 1,840 | 3,547 | 5,807 | 1,916 |
Current Portion of Long-Term Debt | 355.94 | 6,591 | 338.51 | 331.66 | 96.02 |
Current Portion of Leases | 440.88 | 911.85 | 804.99 | 442.6 | 492.23 |
Current Income Taxes Payable | 217.78 | 126.69 | 39.1 | 13.46 | - |
Current Unearned Revenue | 4.17 | 4.17 | 4.32 | 4.28 | 7.53 |
Other Current Liabilities | 6,375 | 1,843 | 2,144 | 4,562 | 1,444 |
Total Current Liabilities | 12,319 | 11,770 | 7,652 | 11,831 | 4,175 |
Long-Term Debt | 6,030 | 9,256 | 6,480 | 7,008 | 3,783 |
Long-Term Leases | 1,084 | 182.49 | 824.86 | 206.79 | 520.66 |
Long-Term Unearned Revenue | 2,041 | 2,046 | 2,050 | 2,054 | 2,058 |
Pension & Post-Retirement Benefits | 2,115 | 2,087 | 1,653 | 1,600 | 1,370 |
Other Long-Term Liabilities | 902.92 | 948.91 | 932.98 | 622.38 | 2,058 |
Total Liabilities | 24,493 | 26,289 | 19,593 | 23,323 | 13,964 |
Common Stock | 6,112 | 5,873 | 5,669 | 5,110 | 5,110 |
Additional Paid-In Capital | 81,523 | 76,481 | 64,803 | 44,478 | 44,478 |
Retained Earnings | -82,945 | -74,983 | -68,269 | -57,759 | -51,485 |
Comprehensive Income & Other | 3,987 | 4,494 | 4,809 | 4,393 | 4,408 |
Total Common Equity | 8,677 | 11,865 | 7,011 | -3,779 | 2,510 |
Minority Interest | 8,049 | 6,447 | 5,343 | 4,814 | 1,321 |
Shareholders' Equity | 16,725 | 18,311 | 12,354 | 1,035 | 3,832 |
Total Liabilities & Equity | 41,219 | 44,601 | 31,947 | 24,358 | 17,796 |
Total Debt | 12,205 | 18,781 | 11,995 | 13,796 | 6,808 |
Net Cash (Debt) | 2,456 | 5,168 | -1,337 | -6,377 | 6,073 |
Net Cash Growth | -52.48% | - | - | - | -11.29% |
Net Cash Per Share | 206.86 | 449.31 | -122.35 | -624.02 | 598.26 |
Filing Date Shares Outstanding | 12.22 | 11.75 | 11.34 | 10.22 | 10.22 |
Total Common Shares Outstanding | 12.22 | 11.75 | 11.34 | 10.22 | 10.22 |
Working Capital | 7,512 | 17,502 | 8,048 | -629.62 | 10,167 |
Book Value Per Share | 709.84 | 1010.11 | 618.41 | -369.73 | 245.64 |
Tangible Book Value | 8,349 | 11,457 | 6,892 | -3,932 | 2,485 |
Tangible Book Value Per Share | 683.06 | 975.39 | 607.93 | -384.77 | 243.15 |
Land | 6,597 | 453.44 | 241.82 | 241.82 | 117.16 |
Buildings | 4,592 | 902.12 | 558.2 | 558.2 | 349.29 |
Machinery | 7,700 | 7,007 | 6,061 | 4,849 | 4,552 |
Construction In Progress | 4,045 | 24 | 829.26 | 441.24 | 42.5 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.